Search results
Results from the WOW.Com Content Network
A therapeutic use exemption (TUE), also known as a temporary use exemption, is a term created in 1991 [1] and refers to an official medical document. The document gives an athlete permission to take a medication listed on the World Anti-Doping Agency’s (WADA) Prohibited List, normally prohibited because its use would be considered a performance enhancing drug.
Attention deficit hyperactivity disorder predominantly inattentive (ADHD-PI or ADHD-I), [3] is one of the three presentations of attention deficit hyperactivity disorder (ADHD). [4] In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R).
In 2007, the case of White et al. v. NCAA, No. CV 06-999-RGK (C.D. Cal. September 20, 2006) was brought by former NCAA student-athletes Jason White, Brian Pollack, Jovan Harris, and Chris Craig as a class action lawsuit. They argued that the NCAA's current limits on a full scholarship or grant-in-aid was a violation of federal antitrust laws.
Logo of the NCAA. In the United States the National Collegiate Athletic Association (NCAA), has since the 1970s been patrolling the usage of illegal drugs and substances for student-athletes attending universities and colleges. In 1999, NCAA Drug Committee published a list containing substances banned for the usage to student-athletes.
Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood, except for when ADHD occurs after traumatic brain injury.
[6] [3] How it works in ADHD is unclear. [3] Dexmethylphenidate was approved for medical use in the United States in 2001. [1] It is available as a generic medication. [3] In 2022, it was the 109th most commonly prescribed medication in the United States, with more than 5 million prescriptions. [7] [8]
Large, high quality research has found small differences in the brain between ADHD and non-ADHD patients. [1] [15] Jonathan Leo and David Cohen, critics who reject the characterization of ADHD as a disorder, contended in 2003 and 2004 that the controls for stimulant medication usage were inadequate in some lobar volumetric studies, which makes it impossible to determine whether ADHD itself or ...
Phenylpiracetam, also known as fonturacetam (INN Tooltip International nonproprietary name) and sold under the brand names Phenotropil, Actitropil, and Carphedon among others, is a stimulant and nootropic medication used in Russia and certain other Eastern European countries in the treatment of cerebrovascular deficiency, depression, apathy, and attention, and memory problems, among other ...